State Street’s Cardiol Therapeutics CRDL Stock Holding History

State Street’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$166K	Buy	+100,000	New	+$159K	﹤0.01%	3954

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.52B AUM 24.83% 1-Year Est. Return

Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $200B AUM 30.19% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.42B AUM 19.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street's CRDL Position: Q3 2026 in Review

State Street opened a new position in Cardiol Therapeutics (CRDL) in Q3 2026: 100,000 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #3954 among its holdings.

36 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

State Street held 100,000 shares of Cardiol Therapeutics worth $166K as of Q3 2026.
Cardiol Therapeutics was a new State Street position in Q3 2026.
Cardiol Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3954 holding.
36 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.